[go: up one dir, main page]

AU2003296553A1 - Increase of the immune response by substances influencing the function of natural killer cells - Google Patents

Increase of the immune response by substances influencing the function of natural killer cells

Info

Publication number
AU2003296553A1
AU2003296553A1 AU2003296553A AU2003296553A AU2003296553A1 AU 2003296553 A1 AU2003296553 A1 AU 2003296553A1 AU 2003296553 A AU2003296553 A AU 2003296553A AU 2003296553 A AU2003296553 A AU 2003296553A AU 2003296553 A1 AU2003296553 A1 AU 2003296553A1
Authority
AU
Australia
Prior art keywords
increase
function
immune response
natural killer
killer cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003296553A
Inventor
Frank Berthold
Markus Jensen
Hans-Harald Sedlacek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medinnova Gesellschaft fuer Medizinische Innovationen aus Akademischer Forschung mbH,
Original Assignee
Medinnova Gesellschaft fuer Medizinische Innovationen aus Akademischer Forschung mbH,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medinnova Gesellschaft fuer Medizinische Innovationen aus Akademischer Forschung mbH, filed Critical Medinnova Gesellschaft fuer Medizinische Innovationen aus Akademischer Forschung mbH,
Publication of AU2003296553A1 publication Critical patent/AU2003296553A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003296553A 2002-12-20 2003-12-19 Increase of the immune response by substances influencing the function of natural killer cells Abandoned AU2003296553A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10261223.4 2002-12-20
DE10261223A DE10261223A1 (en) 2002-12-20 2002-12-20 Increasing the immune response through substances that influence the function of natural killer cells
PCT/DE2003/004268 WO2004056873A1 (en) 2002-12-20 2003-12-19 Increase of the immune response by substances influencing the function of natural killer cells

Publications (1)

Publication Number Publication Date
AU2003296553A1 true AU2003296553A1 (en) 2004-07-14

Family

ID=32478024

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003296553A Abandoned AU2003296553A1 (en) 2002-12-20 2003-12-19 Increase of the immune response by substances influencing the function of natural killer cells

Country Status (4)

Country Link
EP (1) EP1590370A1 (en)
AU (1) AU2003296553A1 (en)
DE (1) DE10261223A1 (en)
WO (1) WO2004056873A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007048849A1 (en) * 2005-10-28 2007-05-03 Novo Nordisk A/S Fusion proteins that bind effector lymphocytes and target cells
CA2708854C (en) 2007-12-14 2017-11-28 Novo Nordisk A/S Antibodies against human nkg2d and uses thereof
HRP20180282T1 (en) 2008-04-17 2018-03-23 Io Biotech Aps INDOLEAMINE 2, 3-DIOXYGENASE IMMUNOTHERAPY
WO2013175237A1 (en) * 2012-05-24 2013-11-28 Ucl Business Plc Composition comprising a cd2 ligation agent and a nkg2d ligation agent
SG11201708804WA (en) 2015-05-07 2017-11-29 Agenus Inc Anti-ox40 antibodies and methods of use thereof
SG10201912984WA (en) 2015-12-02 2020-03-30 Agenus Inc Antibodies and methods of use thereof
CA3041340A1 (en) 2016-11-09 2018-05-17 Agenus Inc. Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
EP4491234A3 (en) 2017-02-08 2025-04-09 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
DK3582806T5 (en) 2017-02-20 2024-09-02 Dragonfly Therapeutics Inc PROTEINS THAT BIND HER2, NKG2D, AND CD16
MX2019014000A (en) * 2017-05-23 2020-07-29 Dragonfly Therapeutics Inc A protein binding nkg2d, cd16 and a tumor-associated antigen.
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
EP3749346B1 (en) 2018-02-08 2024-07-10 Dragonfly Therapeutics, Inc. Antibody variable domain combinations targeting the nkg2d receptor
US12384847B2 (en) 2018-02-08 2025-08-12 Dragonfly Therapeutics, Inc. Cancer therapy involving an anti-PD1 antibody and a multi-specific binding protein that binds NKG2D, CD16, and a tumor-associated antigen
EP3755721A4 (en) 2018-02-20 2021-12-22 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
WO2019178362A1 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
DE202019005887U1 (en) 2018-07-03 2023-06-14 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
AR114544A1 (en) 2018-08-08 2020-09-16 Dragonfly Therapeutics Inc MULTI-SPECIFIC BINDING PROTEINS BINDING BCMA, NKG2D AND CD16, AND METHODS OF USE
EA202091888A1 (en) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. VARIABLE ANTIBODY DOMAINS TARGETED ON THE NKG2D RECEPTOR
AU2019318087B2 (en) 2018-08-08 2025-09-18 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD 16 and a tumor-associated antigen
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
SG11202109033XA (en) * 2019-02-21 2021-09-29 Marengo Therapeutics Inc Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
AU2020224681A1 (en) * 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
CA3166629A1 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
JP2023523011A (en) * 2020-04-24 2023-06-01 マレンゴ・セラピューティクス，インコーポレーテッド Multifunctional molecules that bind to T cell-associated cancer cells and uses thereof
MX2022013944A (en) 2020-05-06 2022-11-30 Dragonfly Therapeutics Inc Proteins binding nkg2d, cd16 and clec12a.
WO2022187539A1 (en) 2021-03-03 2022-09-09 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19531346A1 (en) * 1995-08-25 1997-02-27 Gsf Forschungszentrum Umwelt Medicines for immunotherapy, containing antibodies that specifically recognize the MHCII antigen of a patient to be treated
DE19710497C2 (en) * 1996-09-03 1998-07-09 Gsf Forschungszentrum Umwelt Use bi- and trispecific antibodies to induce tumor immunity
WO2000002923A1 (en) * 1998-07-09 2000-01-20 Nickoloff Brian J Method of treating disorders by modulating the interaction of natural killer receptors on t cells with their respective ligands
DE19859115A1 (en) * 1998-09-25 2000-03-30 Horst Lindhofer Use of delayed tumor cells in combination with intact antibodies for immunization
DE60041655D1 (en) * 1999-11-15 2009-04-09 Innate Pharma TRIGGERING RECEPTOR INVOLVED IN NATURAL CYTOTOXICITY OF NATURAL KILLER CELLS AND ANTIBODIES IDENTIFYING THIS RECEPTOR
AU2002228745A1 (en) * 2000-10-23 2002-05-06 Rajagopalan, Sumati Antibodies and other ligands directed against kir2dl4 receptor for production of interferon gamma

Also Published As

Publication number Publication date
EP1590370A1 (en) 2005-11-02
WO2004056873A1 (en) 2004-07-08
DE10261223A1 (en) 2004-07-08

Similar Documents

Publication Publication Date Title
AU2003296553A1 (en) Increase of the immune response by substances influencing the function of natural killer cells
AU2003237522A1 (en) Salad spinner
AU2003219277A1 (en) Intracellular antibodies
AU2003291563A1 (en) Artificial disc
AU2003272069A1 (en) Novel floating dosage form
AU2003239197A1 (en) Novel stable anti-cd22 antibodies
AU2003222149A1 (en) High level expression of immunogenic proteins in the plastids of higher plants
AU2003261981A1 (en) Transparent eye drops containing latanoprost
AU2003218099A1 (en) Modulation of the immune response through the manipulation of arginine levels
AU2003200567A1 (en) Level
AU2003298202A1 (en) Silicone polymerisates
AU2003255787A1 (en) Modulation of immune function
EP1534330B8 (en) Whole bacterial cells as immune modulator
AU2003256311A1 (en) Mems structure with mechanical overdeflection limiter
AU2003243869A1 (en) Simple pendulum with variable restoring force
AU2003221579A1 (en) Encapsulated cells to elicit immune response
AU2003302234A1 (en) Immune response associated proteins
AU2003269268A1 (en) Modulation of immune function
AU2003202081A1 (en) Improved compression techniques
AU2003208345A1 (en) Tea light
AU2003263030A1 (en) Spacer structure material
AU2003262282A1 (en) Photoelectric transducer
AU2003246971A1 (en) Tranquilliser dart
AU2003268230A1 (en) Immune response associated proteins
AU2002952537A0 (en) The production of fodder

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase